Kidswell Bio: Announcements of individual stocks regarding the recording of non-operating expenses.
Kidswell Bio: Matters related to business plans and growth potential.
Kidswell Bio: Regarding matters related to dominant shareholders.
Kidswell Bio: Announcements of individual stocks regarding the conclusion of a business partnership agreement for joint development of new biosimilars with Kaiom Bioscience Co., Ltd.
Kidswell Bio: Announcements of individual stocks regarding the conclusion of a business consignment contract to strengthen collaboration with the Biologics Research and Training Center (BCRET).
Kidswell Bio: Independent Company Executives Declaration
KIDSWELL BIO: Notice regarding the recording of non-operating expenses
KIDSWELL BIO: Legal post-facto disclosure documents (newly established split) (S-Quatre Co., Ltd.)
KIDSWELL BIO: Legal Advance Disclosure Documents (Newly Established Split) (S-Quatre Co., Ltd.)
Kidswell Bio: Notice Concerning Borrowing of Funds
Kidswell Bio: Notice regarding completion of production of master cell banks for baby tooth pulp stem cells (SHED) in accordance with US FDA standards
Kidswell Bio: Notice regarding the election of candidates for directors and auditors
Kidswell Bio: Notice regarding the recording of non-operating expenses
Kidswell Bio: Supplementary explanatory materials on establishing a subsidiary
Kidswell Bio: Notice regarding the establishment of a subsidiary in the cell therapy business (regenerative medicine) through a company split (simple new establishment split)
Kidswell Bio: Notice regarding loan of funds
Kidswell Bio: Notice regarding organizational changes and personnel changes
Kidswell Bio: Notice regarding the listing of drug price standards and commencement of sales of pegfilgrastim biosimilar (GBS-010)
Kidswell Bio: Notice of the 43rd Japanese Society of Ophthalmic Pharmacology Presentation on Joint Research Results with Gifu Pharmaceutical University -Optic Neuroprotective Effects of Human Milk Dental Pulp Stem Cells-
Kidswell Bio: Notice Concerning the Recording of Non-Operating Expenses and Extraordinary Losses
No Data